Medpace Holdings, Inc. $MEDP Stock: Jefferies Financial Group Inc. Lowers Position

Jefferies Financial Group Inc. lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 76.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 870 shares of the company’s stock after selling 2,830 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Medpace were worth $543,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its stake in shares of Medpace by 38.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock valued at $10,615,000 after buying an additional 5,610 shares in the last quarter. American Capital Management Inc. acquired a new position in Medpace in the second quarter worth approximately $111,329,000. Focus Partners Advisor Solutions LLC bought a new position in Medpace during the second quarter valued at approximately $1,685,000. Rice Hall James & Associates LLC bought a new position in Medpace during the second quarter valued at approximately $28,659,000. Finally, Odyssean LLC bought a new position in Medpace during the second quarter valued at approximately $3,369,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

MEDP opened at $653.94 on Monday. The company has a market cap of $18.29 billion, a PE ratio of 36.25, a price-to-earnings-growth ratio of 2.54 and a beta of 1.12. The stock has a 50-day moving average of $629.52 and a 200-day moving average of $533.79. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $693.97.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The business had revenue of $716.00 million for the quarter, compared to analyst estimates of $714.47 million. During the same quarter in the prior year, the firm posted $3.86 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, research analysts predict that Medpace Holdings, Inc. will post 18.06 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial increased their price target on shares of Medpace from $609.00 to $633.00 and gave the stock a “hold” rating in a research note on Friday, October 23rd. Deutsche Bank restated a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen raised their price target on shares of Medpace from $492.00 to $673.00 and gave the company a “hold” rating in a report on Friday, October 23rd. Finally, BMO Capital Markets lifted their price objective on shares of Medpace from $600.00 to $670.00 and gave the company a “market perform” rating in a research note on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $649.27.

Read Our Latest Analysis on MEDP

Insider Buying and Selling

In other Medpace news, CEO August Troendle sold 21,966 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the completion of the sale, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. This represents a 6.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Stephen Ewald sold 1,245 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $690.00, for a total value of $859,050.00. Following the sale, the general counsel directly owned 19,098 shares of the company’s stock, valued at $13,177,620. The trade was a 6.12% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 306,539 shares of company stock worth $191,774,429. 20.50% of the stock is currently owned by insiders.

About Medpace

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

See Also

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.